Geroprotective Agents, Including Glucagon-Like Peptide-1 Receptor Agonists, For Ocular Health
Many of us are familiar with medications initially developed for conditions like diabetes and obesity. These drugs, known as glucagon-like peptide-1 receptor agonists (GLP-1RAs), are gaining attention for their potential effects on eye health. Beyond their primary roles in managing blood sugar and weight, these agents possess properties that can reduce inflammation, act as antioxidants, and protect nerve cells, which are all crucial for maintaining healthy eyes.
Researchers are exploring how these medications might influence common age-related eye diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration. For instance, some studies suggest a reduced risk of glaucoma in individuals using GLP-1RAs. However, the picture is more complex for other conditions like diabetic retinopathy, where there might be both potential long-term benefits and a risk of temporary worsening in the early stages of treatment. There have also been some unconfirmed reports of a serious eye condition called nonarteritic anterior ischemic optic neuropathy associated with their use.
This emerging area of research highlights the need for continued investigation to fully understand the benefits and risks of these widely used medications for our vision. It also underscores the importance for healthcare providers to consider these ocular effects when prescribing such treatments.
Source: link to paper